Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications

References

• Burchert A, Bug G, Fritz LV, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002. doi:10.1200/JCO.19.03345
   PubMed Web of Science ®Google Scholar
• Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20–28. doi:10.1016/j.ctrv.2019.05.004
   PubMed Web of Science ®Google Scholar
• Fu M, Guo J, Zhao Y, et al. Characteristics of Fall-Related Fractures in Older Adults with Cerebrovascular Disease: a Cross-Sectional Study. Clin Interv Aging. 2021;16:1337–1346. doi:10.2147/CIA.S316739
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The molecular basis of oncogenes and tumor suppressor genes. Ann N Y Acad Sci. 1995;758:331–338. doi:10.1111/j.1749-6632.1995.tb24838.x
   PubMed Web of Science ®Google Scholar
• Escalante CP, Chang YC, Liao K, et al. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24(9):4057–4074. doi:10.1007/s00520-016-3310-3
   PubMed Web of Science ®Google Scholar
• Smith RA, Barbosa J, Blum CL, et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg Med Chem Lett. 2001;11(20):2775–2778. doi:10.1016/s0960-894x(01)00571-6
   PubMed Web of Science ®Google Scholar
• Wang L, Chen M, Ran X, Tang H, Cao D. Sorafenib-Based Drug Delivery Systems: applications and Perspectives. Polymers (Basel). 2023;15(12). doi:10.3390/polym15122638
   Web of Science ®Google Scholar
• Baek Moller N, Budolfsen C, Grimm D, et al. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment. Int J Mol Sci. 2019;20(19). doi:10.3390/ijms20194712
   PubMed Web of Science ®Google Scholar
• Li Y, Li S, Zhu Y, et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2014;16(3):177–185. doi:10.1111/jch.12273
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang C, Zhang A, et al. ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. Biomed Pharmacother. 2022;153:113280. doi:10.1016/j.biopha.2022.113280
   PubMed Web of Science ®Google Scholar
• Saha D, Ryan KR, Lakkaniga NR, et al. Targeting Rearranged during Transfection in Cancer: a Perspective on Small-Molecule Inhibitors and Their Clinical Development. J Med Chem. 2021;64(16):11747–11773. doi:10.1021/acs.jmedchem.0c02167
   PubMed Web of Science ®Google Scholar
• Chen YT, Masbuchin AN, Fang YH, et al. Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways. Biomed Pharmacother. 2023;157:113962. doi:10.1016/j.biopha.2022.113962
   PubMed Web of Science ®Google Scholar
• Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res. 2009;15(19):5947–5949. doi:10.1158/1078-0432.CCR-09-1717
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: a Report From the American Heart Association. Circulation. 2020;141(9):e139–e596. doi:10.1161/CIR.0000000000000757
   PubMed Web of Science ®Google Scholar
• Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19(2):177–189. doi:10.1080/14737140.2019.1559058
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223–240. doi:10.2165/00003495-200969020-00006
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Watanabe T, Nishida K, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest. 2004;114(7):937–943. doi:10.1172/JCI20317
   PubMed Web of Science ®Google Scholar
• Sathishkumar K, Yallampalli U, Elkins R, Yallampalli C. Raf-1 kinase regulates smooth muscle contraction in the rat mesenteric arteries. J Vasc Res. 2010;47(5):384–398. doi:10.1159/000277726
   PubMed Web of Science ®Google Scholar
• Dong LH, Wen JK, Liu G, et al. Blockade of the Ras-extracellular signal-regulated kinase 1/2 pathway is involved in smooth muscle 22 alpha-mediated suppression of vascular smooth muscle cell proliferation and neointima hyperplasia. Arterioscler Thromb Vasc Biol. 2010;30(4):683–691. doi:10.1161/ATVBAHA.109.200501
   PubMed Web of Science ®Google Scholar
• Elaimy AL, Mercurio AM. Convergence of VEGF and YAP/TAZ signaling: implications for angiogenesis and cancer biology. Sci Signal. 2018;11(552). doi:10.1126/scisignal.aau1165
   Web of Science ®Google Scholar
• Li Y, Gao ZH, Qu XJ. The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol. 2015;116(3):216–221. doi:10.1111/bcpt.12365
   PubMed Web of Science ®Google Scholar
• Zou J, Fei Q, Xiao H, et al. VEGF-A promotes angiogenesis after acute myocardial infarction through increasing ROS production and enhancing ER stress-mediated autophagy. J Cell Physiol. 2019;234(10):17690–17703. doi:10.1002/jcp.28395
   PubMed Web of Science ®Google Scholar
• Naito H, Iba T, Takakura N. Mechanisms of new blood-vessel formation and proliferative heterogeneity of endothelial cells. Int Immunol. 2020;32(5):295–305. doi:10.1093/intimm/dxaa008
   PubMed Web of Science ®Google Scholar
• Chirkov YY, Nguyen TH, Horowitz JD. Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: mechanisms and Clinical Implications in Cardiovascular Disease. Int J Mol Sci. 2022;23(3):1042. doi:10.3390/ijms23031042
   PubMed Web of Science ®Google Scholar
• Tian M, Chen K, Huang J, et al. Asiatic acid inhibits angiogenesis and vascular permeability through the VEGF/VEGFR2 signaling pathway to inhibit the growth and metastasis of breast cancer in mice. Phytother Res. 2021;35(11):6389–6400. doi:10.1002/ptr.7292
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–3318. doi:10.1200/JCO.2008.19.5511
   PubMed Web of Science ®Google Scholar
• Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25(5):482–494. doi:10.1177/2047487318755193
   PubMed Web of Science ®Google Scholar
• Maraiki F, Aljubran A. Carotid and brachiocephalic arteries stenosis with long term use of sorafenib. Hematol Oncol Stem Cell Ther. 2014;7(1):53–55. doi:10.1016/j.hemonc.2013.06.005
   PubMedGoogle Scholar
• Jensen BC, Parry TL, Huang W, et al. Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis. Br J Pharmacol. 2017;174(24):4797–4811. doi:10.1111/bph.14062
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol. 2014;10(12):1981–1992. doi:10.2217/fon.14.42
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–123. doi:10.1016/S1470-2045(08)70003-2
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011;78(1):24–32. doi:10.1016/j.critrevonc.2010.03.006
   PubMed Web of Science ®Google Scholar
• Akutsu N, Sasaki S, Takagi H, et al. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol. 2015;20(1):105–110. doi:10.1007/s10147-014-0691-5
   PubMed Web of Science ®Google Scholar
• Carballo-Folgoso L, Alvarez-Velasco R, Lorca R, et al. Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study. Liver Int. 2021;41(9):2200–2211. doi:10.1111/liv.14941
   PubMed Web of Science ®Google Scholar
• Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72–78. doi:10.1016/j.jchf.2012.09.001
   PubMed Web of Science ®Google Scholar
• Fu Y, Wei X, Lin L, Xu W, Liang J. Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors. Thorac Cancer. 2018;9(5):542–547. doi:10.1111/1759-7714.12608
   PubMed Web of Science ®Google Scholar
• Santoni M, Conti A, Massari F, et al. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Rev Cardiovasc Ther. 2019;17(12):917–927. doi:10.1080/14779072.2019.1704626
   PubMed Web of Science ®Google Scholar
• Yang X, Pan X, Cheng X, Kuang Y, Cheng Y. Risk of Hypertension With Sorafenib Use in Patients With Cancer: a Meta-Analysis From 20,494 Patients. Am J Ther. 2017;24(1):e81–e101. doi:10.1097/MJT.0000000000000331
   PubMed Web of Science ®Google Scholar
• Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician’s perspective. Semin Oncol. 2014;41 Suppl 2:S1–S16. doi:10.1053/j.seminoncol.2014.01.001
   PubMedGoogle Scholar
• Duran JM, Makarewich CA, Trappanese D, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res. 2014;114(11):1700–1712. doi:10.1161/CIRCRESAHA.114.303200
   PubMed Web of Science ®Google Scholar
• Yokoyama H, Shioyama W, Shintani T, et al. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions. Int Heart J. 2021;62(6):1297–1304. doi:10.1536/ihj.21-307
   PubMed Web of Science ®Google Scholar
• Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348–351. doi:10.1007/s00059-011-3444-5
   PubMed Web of Science ®Google Scholar
• Arima Y, Oshima S, Noda K, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54(3):512–515. doi:10.1016/j.jjcc.2009.03.009
   PubMed Web of Science ®Google Scholar
• Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409–425. doi:10.1016/j.jash.2018.03.008
   PubMed Web of Science ®Google Scholar
• Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22(1):115–128. doi:10.1016/j.beha.2009.01.001
   PubMed Web of Science ®Google Scholar
• Das A, Mahapatra S, Bandyopadhyay D, et al. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis. Crit Rev Oncol Hematol. 2021;157:103186. doi:10.1016/j.critrevonc.2020.103186
   PubMed Web of Science ®Google Scholar
• Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009;10(10):967–974. doi:10.1016/S1470-2045(09)70222-0
   PubMed Web of Science ®Google Scholar
• Kloth JS, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011–1016. doi:10.1038/bjc.2015.82
   PubMed Web of Science ®Google Scholar
• Jang S, Zheng C, Tsai HT, et al. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer. 2016;122(1):124–130. doi:10.1002/cncr.29728
   PubMed Web of Science ®Google Scholar
• Wang H, Sheehan RP, Palmer AC, et al. Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming. Cell Syst. 2019;8(5):412–426 e417. doi:10.1016/j.cels.2019.03.009
   PubMed Web of Science ®Google Scholar
• Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. doi:10.1038/s41698-018-0056-z
   PubMed Web of Science ®Google Scholar
• Mercurio V, Pirozzi F, Lazzarini E, et al. Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. J Card Fail. 2016;22(6):449–458. doi:10.1016/j.cardfail.2016.04.008
   PubMed Web of Science ®Google Scholar
• Tomita Y, Naito S, Sassa N, et al. Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: multicenter Randomized Trial CROSS-J-RCC. Clin Genitourin Cancer. 2020;18(4):e374–e385. doi:10.1016/j.clgc.2020.01.001
   PubMed Web of Science ®Google Scholar
• Wu C, Shemisa K. Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: a Clinical Case Discussion. Case Rep Cardiol. 2017;2017:7065759. doi:10.1155/2017/7065759
   PubMedGoogle Scholar
• Sudasena D, Balanescu DV, Donisan T, et al. Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. Cardiovasc Toxicol. 2019;19(4):382–387. doi:10.1007/s12012-018-9499-2
   PubMed Web of Science ®Google Scholar
• Destere A, Merino D, Lavrut T, et al. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review. Therapie. 2023. doi:10.1016/j.therap.2023.10.008
   Google Scholar
• Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895–903. doi:10.1093/cvr/cvz013
   PubMed Web of Science ®Google Scholar
• Pabinger I, van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289–e298. doi:10.1016/S2352-3026(18)30063-2
   PubMed Web of Science ®Google Scholar
• Scheiner B, Northup PG, Gruber AB, et al. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Liver Int. 2020;40(6):1415–1426. doi:10.1111/liv.14404
   PubMed Web of Science ®Google Scholar
• Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017;219(1):22–96. doi:10.1111/apha.12646
   PubMed Web of Science ®Google Scholar
• Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med. 2016;375(15):1457–1467. doi:10.1056/NEJMra1100265
   PubMed Web of Science ®Google Scholar
• Quintanilha JCF, Racioppi A, Wang J, et al. PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors. Pharmacogenomics J. 2022;22(1):82–88. doi:10.1038/s41397-021-00261-5
   PubMed Web of Science ®Google Scholar
• Miller TW, Cherney MM, Lee AJ, et al. The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: interactions at ferrous heme and cysteine thiols. J Biol Chem. 2009;284(33):21788–21796. doi:10.1074/jbc.M109.014282
   PubMed Web of Science ®Google Scholar
• Yu Q, Li K, Zhao A, et al. Sorafenib not only impairs endothelium-dependent relaxation but also promotes vasoconstriction through the upregulation of vasoconstrictive endothelin type B receptors. Toxicol Appl Pharmacol. 2021;414:115420. doi:10.1016/j.taap.2021.115420
   PubMed Web of Science ®Google Scholar
• Abdel-Samad D, Bkaily G, Magder S, Jacques D. ETA and ETB receptors contribute to neuropeptide Y-induced secretion of endothelin-1 in right but not left human ventricular endocardial endothelial cells. Neuropeptides. 2016;55:145–153. doi:10.1016/j.npep.2016.01.001
   PubMed Web of Science ®Google Scholar
• Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992;186(2):867–873. doi:10.1016/0006-291x(92)90826-7
   PubMed Web of Science ®Google Scholar
• Houde M, Desbiens L, D’Orleans-Juste P. Endothelin-1: biosynthesis, Signaling and Vasoreactivity. Adv Pharmacol. 2016;77:143–175. doi:10.1016/bs.apha.2016.05.002
   PubMedGoogle Scholar
• Van Leeuwen MT, Luu S, Gurney H, et al. Cardiovascular Toxicity of Targeted Therapies for Cancer: an Overview of Systematic Reviews. JNCI Cancer Spectr. 2020;4(6):pkaa076. doi:10.1093/jncics/pkaa076
   PubMed Web of Science ®Google Scholar
• Imran TF, Shah R, Ha AS, Thomas R, Joseph J. Heart failure associated with small molecule tyrosine kinase inhibitors. Int J Cardiol. 2016;206:110–111. doi:10.1016/j.ijcard.2016.01.059
   PubMed Web of Science ®Google Scholar
• Li Y, Xia J, Shao F, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem Biophys Res Commun. 2021;534:877–884. doi:10.1016/j.bbrc.2020.10.083
   PubMed Web of Science ®Google Scholar
• Kawabata M, Umemoto N, Shimada Y, et al. Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. Toxicol Sci. 2015;143(2):374–384. doi:10.1093/toxsci/kfu235
   PubMed Web of Science ®Google Scholar
• French KJ, Coatney RW, Renninger JP, et al. Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicol Pathol. 2010;38(5):691–702. doi:10.1177/0192623310373775
   PubMed Web of Science ®Google Scholar
• Ma W, Liu M, Liang F, et al. Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis. Basic Clin Pharmacol Toxicol. 2020;126(2):166–180. doi:10.1111/bcpt.13318
   PubMed Web of Science ®Google Scholar
• Bouitbir J, Panajatovic MV, Krahenbuhl S. Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line. Int J Mol Sci. 2022;23(4). doi:10.3390/ijms23042282
   Web of Science ®Google Scholar
• Dai N, Ye R, He Q, Guo P, Chen H, Zhang Q. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling. Oncol Rep. 2018;40(6):3235–3248. doi:10.3892/or.2018.6754
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhou Q, Gao A, Chen L, Li L. Endoplasmic reticulum stress and focused drug discovery in cardiovascular disease. Clin Chim Acta. 2020;504:125–137. doi:10.1016/j.cca.2020.01.031
   PubMed Web of Science ®Google Scholar
• Ren J, Bi Y, Sowers JR, Hetz C, Zhang Y. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat Rev Cardiol. 2021;18(7):499–521. doi:10.1038/s41569-021-00511-w
   PubMed Web of Science ®Google Scholar
• Wang H, Wang Y, Li J, et al. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC Med. 2023;21(1):147. doi:10.1186/s12916-023-02838-2
   PubMed Web of Science ®Google Scholar
• Gatica D, Chiong M, Lavandero S, Klionsky DJ. The role of autophagy in cardiovascular pathology. Cardiovasc Res. 2022;118(4):934–950. doi:10.1093/cvr/cvab158
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang Q, Jia R, Xiang S, Xu L. A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy. Front Cell Dev Biol. 2023;11:1156383. doi:10.3389/fcell.2023.1156383
   PubMed Web of Science ®Google Scholar
• Fornari F, Giovannini C, Piscaglia F, Gramantieri L. Elucidating the Molecular Basis of Sorafenib Resistance in HCC: current Findings and Future Directions. J Hepatocell Carcinoma. 2021;8:741–757. doi:10.2147/JHC.S285726
   PubMed Web of Science ®Google Scholar
• Booth LA, Roberts JL, Dent P. The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib. Semin Cancer Biol. 2020;66:129–139. doi:10.1016/j.semcancer.2019.10.013
   PubMed Web of Science ®Google Scholar
• Liang F, Zhang K, Ma W, et al. Impaired autophagy and mitochondrial dynamics are involved in Sorafenib-induced cardiomyocyte apoptosis. Toxicology. 2022;481:153348. doi:10.1016/j.tox.2022.153348
   PubMed Web of Science ®Google Scholar
• Li DL, Hill JA. Cardiomyocyte autophagy and cancer chemotherapy. J Mol Cell Cardiol. 2014;71:54–61. doi:10.1016/j.yjmcc.2013.11.007
   PubMed Web of Science ®Google Scholar
• Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88. doi:10.1038/s41419-020-2298-2
   PubMed Web of Science ®Google Scholar
• Xia Y, Wang G, Jiang M, et al. A Novel Biological Activity of the STAT3 Inhibitor Stattic in Inhibiting Glutathione Reductase and Suppressing the Tumorigenicity of Human Cervical Cancer Cells via a ROS-Dependent Pathway. Onco Targets Ther. 2021;14:4047–4060. doi:10.2147/OTT.S313507
   PubMed Web of Science ®Google Scholar
• Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052–3059. doi:10.7150/thno.54113
   PubMed Web of Science ®Google Scholar
• Li Y, Yan J, Zhao Q, Zhang Y, Zhang Y. ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression. Front Pharmacol. 2022;13:904314. doi:10.3389/fphar.2022.904314
   PubMed Web of Science ®Google Scholar
• Frontiers Editorial O. Retraction: overexpression of SERCA2a alleviates cardiac microvascular ischemic injury by suppressing Mfn2-mediated ER/mitochondrial calcium tethering. Front Cell Dev Biol. 2022;10:1006540. doi:10.3389/fcell.2022.1006540
   PubMed Web of Science ®Google Scholar
• Zaafar D, Khalil HMA, Rasheed RA, Eltelbany RFA, Zaitone SA. Hesperetin mitigates sorafenib-induced cardiotoxicity in mice through inhibition of the TLR4/NLRP3 signaling pathway. PLoS One. 2022;17(8):e0271631. doi:10.1371/journal.pone.0271631
   PubMed Web of Science ®Google Scholar
• Grabowska ME, Chun B, Moya R, Saucerman JJ. Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity. J Mol Cell Cardiol. 2021;155:66–77. doi:10.1016/j.yjmcc.2021.02.014
   PubMed Web of Science ®Google Scholar
• Abdelgalil AA, Mohamed OY, Ahamad SR, Al-Jenoobi FI. The protective effect of losartan against sorafenib induced cardiotoxicity: ex-vivo isolated heart and metabolites profiling studies in rat. Eur J Pharmacol. 2020;882:173229. doi:10.1016/j.ejphar.2020.173229
   PubMed Web of Science ®Google Scholar
• Lewinter C, Nielsen TH, Edfors LR, et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J. 2022;43(27):2562–2569. doi:10.1093/eurheartj/ehab843
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Hye Khan MA, Imig JD. Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol. 2012;39(5):454–461. doi:10.1111/j.1440-1681.2012.05699.x
   PubMed Web of Science ®Google Scholar
• Szmit S, Zaborowska M, Wasko-Grabowska A, et al. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. Kidney Blood Press Res. 2012;35(6):468–476. doi:10.1159/000338175
   PubMed Web of Science ®Google Scholar
• Chen Z, Yuan T, Yan F, et al. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling. BMC Cancer. 2022;22(1):425. doi:10.1186/s12885-022-09520-5
   PubMed Web of Science ®Google Scholar
• Mendez-Blanco C, Fondevila F, Garcia-Palomo A, Gonzalez-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50(10):1–9. doi:10.1038/s12276-018-0159-1
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis. 2020;11(10):902. doi:10.1038/s41419-020-03123-3
   PubMed Web of Science ®Google Scholar
• Xu R, Yuan W, Wang Z. Advances in Glycolysis Metabolism of Atherosclerosis. J Cardiovasc Transl Res. 2023;16(2):476–490. doi:10.1007/s12265-022-10311-3
   PubMed Web of Science ®Google Scholar
• Zhang X, Zheng B, Zhao L, et al. KLF4-PFKFB3-driven glycolysis is essential for phenotypic switching of vascular smooth muscle cells. Commun Biol. 2022;5(1):1332. doi:10.1038/s42003-022-04302-y
   PubMed Web of Science ®Google Scholar
• Schnitzler JG, Hoogeveen RM, Ali L, et al. Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circ Res. 2020;126(10):1346–1359. doi:10.1161/CIRCRESAHA.119.316206
   PubMed Web of Science ®Google Scholar
• Yu Q. Sorafenib Aggravates Atherosclerotic Progression Involving With Vascular Smooth Muscle Cell (VSMCs) Phenotypic Switching and Proliferation by PKM2-Mediated Glycolysis. Circulation. 2023;148(Suppl_1):10009–17322.
   Google Scholar
• He Y, Wang X, Lu W, et al. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell Death Dis. 2022;13(2):118. doi:10.1038/s41419-022-04576-4
   PubMed Web of Science ®Google Scholar
• Tan XP, Xiong BH, Zhang YX, Wang SL, Zuo Q, Li J. FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. Eur J Pharmacol. 2022;931:175186. doi:10.1016/j.ejphar.2022.175186
   PubMed Web of Science ®Google Scholar
• Zhu Y, Xu J, Hu W, et al. TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction. Gene. 2020;753:144807. doi:10.1016/j.gene.2020.144807
   PubMed Web of Science ®Google Scholar
• Xu J, Ji L, Ruan Y, et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1beta in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):190. doi:10.1038/s41392-021-00594-4
   PubMed Web of Science ®Google Scholar
• Tan W, Luo X, Li W, et al. TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2019;40:446–456. doi:10.1016/j.ebiom.2018.12.047
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen P, Hu K, et al. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. J Cell Mol Med. 2021;25(3):1568–1582. doi:10.1111/jcmm.16256
   PubMed Web of Science ®Google Scholar
• Lo J, Lau EY, Ching RH, et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Hepatology. 2015;62(2):534–545. doi:10.1002/hep.27859
   PubMed Web of Science ®Google Scholar
• Neves KB, Montezano AC, Lang NN, Touyz RM. Vascular toxicity associated with anti-angiogenic drugs. Clin Sci (Lond). 2020;134(18):2503–2520. doi:10.1042/CS20200308
   PubMed Web of Science ®Google Scholar
• Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120–127. doi:10.1016/j.ctrv.2016.12.002
   PubMed Web of Science ®Google Scholar
• Jiang L, Ping L, Yan H, et al. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opin Drug Metab Toxicol. 2020;16(9):823–835. doi:10.1080/17425255.2020.1787986
   PubMed Web of Science ®Google Scholar
• Zhong L, Li Y, Xiong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. doi:10.1038/s41392-021-00572-w
   PubMed Web of Science ®Google Scholar
• Brinda BJ, Viganego F, Vo T, Dolan D, Fradley MG. Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options. Curr Treat Options Cardiovasc Med. 2016;18(5):33. doi:10.1007/s11936-016-0452-z
   PubMedGoogle Scholar